← Back to all trials
Active Not Recruiting
NCT05335876
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
Conditions: Spinal Muscular Atrophy (SMA)
Sex: All
Ages: 0 Years – 100 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 20
Sponsor: Novartis Pharmaceuticals
Location: Child Hosp Of The Kings Daughters Norfolk Virginia
Summary
This is a global, prospective, multi-center study that is designed to assess the long-term safety and efficacy of OAV101 in patients who participated in an OAV101 clinical trial. The assessments of safety and efficacy in Study COAV101A12308 will continue for 5 years after enrollment in this study.
Eligibility Criteria
Inclusion Criteria:
1. Participated in an OAV101 clinical trial.
2. Written informed consent must be obtained before any assessment is performed.
3. Patient/Parent/legal guardian willing and able to comply with study procedures.
Exclusion Criteria:
There are no exclusion criteria for this study.
Source: ClinicalTrials.gov (NCT05335876). StuddyBuddy aggregates publicly available trial information.
